TMEM70: A Critical Assembly Factor for Mitochondrial ATP Synthase

Introduction and Summary

TMEM70 (Transmembrane protein 70, mitochondrial; UniProt: Q9BUB7) is a nuclear-encoded protein of approximately 21-30 kDa that functions as an essential assembly factor for the mitochondrial F1Fo-ATP synthase (Complex V) [cizkova-2008-discovery-abstract]. This protein was first identified in 2008 through whole-genome homozygosity mapping in patients with isolated mitochondrial ATP synthase deficiency presenting as neonatal encephalocardiomyopathy [cizkova-2008-discovery-abstract]. TMEM70 is localized in the inner mitochondrial membrane, specifically within the cristae membranes, where it plays a pivotal role in facilitating the assembly of the c-ring component of the Fo proton channel [bahri-2020-scaffold-abstract]. Mutations in TMEM70 represent the most common nuclear genetic cause of isolated ATP synthase deficiency, with the disease manifesting primarily as severe neonatal lactic acidosis, hypertrophic cardiomyopathy, and encephalopathy [tauchmannova-2024-review-abstract].

The primary molecular function of TMEM70 is to serve as an oligomeric scaffold that promotes the stepwise assembly of subunit c into the c-ring, the essential rotor component of the ATP synthase proton translocation domain [kovalcikova-2019-subunitc-abstract]. Without functional TMEM70, cells accumulate the F1 catalytic domain and peripheral stalk but fail to properly incorporate the Fo membrane domain, resulting in severely impaired ATP synthesis capacity. Recent evidence also suggests that TMEM70 may have a role in Complex I assembly, indicating a broader function in oxidative phosphorylation system biogenesis [sanchez-caballero-2020-complexI-abstract].

Molecular Function: ATP Synthase Assembly

Role in c-Ring Assembly

The mitochondrial F1Fo-ATP synthase is a remarkable molecular machine that harnesses the proton gradient across the inner mitochondrial membrane to synthesize ATP from ADP and inorganic phosphate. The enzyme consists of two major domains: the membrane-extrinsic F1 catalytic domain (containing the α, β, γ, δ, and ε subunits) and the membrane-embedded Fo proton channel (containing subunits a, c, and accessory subunits). The Fo domain includes the c-ring, composed of 8 identical copies of the highly hydrophobic subunit c, which rotates as protons flow through the channel to drive ATP synthesis [bahri-2020-scaffold-abstract].

Studies using TMEM70 conditional knockout mice have definitively established that TMEM70 functions at an early stage of ATP synthase biogenesis by promoting the incorporation of subunit c into the rotor structure [kovalcikova-2019-subunitc-abstract]. In the absence of TMEM70, cells form an incomplete enzyme complex consisting of the F1 domain and peripheral stalk but lacking the Fo proton channel. This results in an 80% decrease in fully assembled ATP synthase and a marked accumulation of F1 complexes [vrbacky-2016-knockout-abstract]. Critically, direct interaction between TMEM70 and subunit c has been demonstrated through immunoprecipitation and pulse-chase experiments, with TMEM70-subunit c complexes containing progressively increasing amounts of subunit c detected, suggesting a role for TMEM70 oligomers in the gradual assembly of the c-ring [bahri-2020-scaffold-abstract].

The biological significance of TMEM70 lies in its ability to increase the low efficacy of spontaneous subunit c oligomer assembly, which represents the key rate-limiting step of ATP synthase biogenesis [kovalcikova-2019-subunitc-abstract]. Overexpression of subunit c can partially rescue the TMEM70 defect in cultured cells, further supporting this model [kovalcikova-2019-subunitc-abstract].

High Molecular Weight Complexes

TMEM70 forms large oligomeric complexes that function as scaffolds for c-ring assembly. On Blue-Native PAGE, TMEM70 is detected in multiple forms including dimers, and these complexes display partial overlap with assembled ATP synthase [kratochvilova-2014-topology-abstract]. Studies in HeLa cells have shown that mutant TMEM70 associates in high molecular weight complexes of 470-550 kDa [torraco-2012-hotspot-abstract]. Interestingly, immunoprecipitation and immunogold electron microscopy studies indicate that while TMEM70 molecules interact with each other, there is no direct stable interaction with fully assembled ATP synthase subunits, suggesting that TMEM70's function is transient and specific to the assembly process [kratochvilova-2014-topology-abstract].

Partnership with TMEM242

A significant mechanistic advance came from the discovery that TMEM70 works in partnership with another mitochondrial transmembrane protein, TMEM242 [carroll-2021-tmem242-abstract]. Both proteins interact with subunit c and contribute to c-ring assembly, though with distinct but overlapping functions. Deletion of either TMEM70 or TMEM242 individually reduces but does not completely eliminate ATP synthase assembly. However, simultaneous deletion of both proteins completely prevents ATP synthase assembly, demonstrating their essential and partially redundant roles in c-ring formation [carroll-2021-tmem242-abstract]. Interestingly, TMEM242 (but not TMEM70) also affects the introduction of subunits ATP6, ATP8, j, and k into the enzyme, indicating that TMEM242 has additional functions in later stages of ATP synthase assembly [carroll-2021-tmem242-abstract].

Dual Role in Complexes I and V

Beyond its established role in ATP synthase assembly, recent evidence from BioID proximity labeling, complexome profiling, and coevolution analyses has revealed that TMEM70 also functions in the assembly of respiratory chain Complex I (NADH:ubiquinone oxidoreductase) [sanchez-caballero-2020-complexI-abstract]. Loss of TMEM70 results in the accumulation of an assembly intermediate followed by a reduction of the next assembly intermediate for both complexes I and V, indicating that TMEM70 has a role in the stability of membrane-bound subassemblies or in the membrane recruitment of subunits into forming complexes [sanchez-caballero-2020-complexI-abstract]. This dual function provides an explanation for the observation that some TMEM70 patient tissues show deficiencies in multiple OXPHOS complexes rather than isolated Complex V defects [diodato-2014-italian-abstract].

Importantly, both TMEM70 and TMEM242 interact with the mitochondrial complex I assembly (MCIA) complex, which supports assembly of the membrane arm of Complex I [carroll-2021-tmem242-abstract]. The double deletion of TMEM70 and TMEM242 enhances the impact on Complex I assembly beyond that seen with single deletions [carroll-2021-tmem242-abstract]. These interactions provide a molecular explanation for the coordinate regulation of Complex I and Complex V assembly and suggest that TMEM70 and TMEM242 may serve as a hub for OXPHOS membrane complex biogenesis.

Subcellular Localization and Membrane Topology

Inner Mitochondrial Membrane Localization

TMEM70 is localized to the inner mitochondrial membrane, a finding confirmed through multiple approaches including immunogold labeling experiments and comparative genomics analysis [jonckheere-2011-topology-abstract]. More specifically, expansion super-resolution microscopy has demonstrated that TMEM70 localizes specifically at the inner cristae membrane, distinct from the MICOS component MIC60 which marks cristae junctions [bahri-2020-scaffold-abstract]. This cristae localization is significant because ATP synthase is known to be enriched at the edges of cristae where it plays a key role in cristae structure and stability [bahri-2020-scaffold-abstract].

Membrane Topology

Topological studies using tagged forms of TMEM70 have established that the protein adopts a hairpin structure with both the N- and C-termini oriented towards the mitochondrial matrix [kratochvilova-2014-topology-abstract]. This topology positions TMEM70 to interact with newly synthesized subunit c and facilitate its incorporation into the growing c-ring within the inner membrane.

Gene Ontology Annotation Summary

The functional annotations for TMEM70 (Q9BUB7) in the Gene Ontology database, derived from experimental evidence, provide a concise summary of its characterized functions:

Molecular Function: TMEM70 has been annotated with protein binding activity (GO:0005515) based on physical interaction evidence from multiple studies [kovalcikova-2019-subunitc-abstract][bahri-2020-scaffold-abstract][carroll-2021-tmem242-abstract]. It also functions as a protein-macromolecule adaptor (GO:0030674), mediating interactions between subunit c and the growing c-ring complex [sanchez-caballero-2020-complexI-abstract]. Additionally, TMEM70 has been shown to bind to the mitochondrial proton-transporting ATP synthase complex (GO:0140260) [sanchez-caballero-2020-complexI-abstract].

Biological Process: TMEM70 participates in mitochondrial proton-transporting ATP synthase complex assembly (GO:0033615), supported by extensive mutant phenotype evidence from both human patients and knockout mice [cizkova-2008-discovery-abstract][kovalcikova-2019-subunitc-abstract][vrbacky-2016-knockout-abstract]. It also contributes to mitochondrial respiratory chain complex I assembly (GO:0032981) [sanchez-caballero-2020-complexI-abstract]. TMEM70 itself undergoes protein complex oligomerization (GO:0051259) and protein homooligomerization (GO:0051260), forming the scaffolds essential for its assembly function [kratochvilova-2014-topology-abstract][bahri-2020-scaffold-abstract].

Cellular Component: TMEM70 is localized to the mitochondrial inner membrane (GO:0005743) and more specifically to the mitochondrial crista (GO:0030061), as confirmed by immunogold labeling and super-resolution microscopy [kratochvilova-2014-topology-abstract][bahri-2020-scaffold-abstract].

Evolutionary Conservation and Protein Family

TMEM70 belongs to the TMEM70/TMEM186/TMEM223 protein family, with all three members being mitochondrial in humans [sanchez-caballero-2020-complexI-abstract]. Evolutionary analyses demonstrate that this protein family only occurs in species with oxidative phosphorylation complexes, providing independent evidence for a role in OXPHOS assembly [sanchez-caballero-2020-complexI-abstract]. While initial phylogenetic analyses suggested that TMEM70 was specific for higher eukaryotes [houstek-2009-ancillary-abstract], subsequent comparative genomics studies have revealed that the gene is not restricted to higher multicellular eukaryotes and is also found in simpler organisms [jonckheere-2011-topology-abstract].

Consequences of TMEM70 Deficiency

Effects on Mitochondrial Structure

Loss of TMEM70 function has profound effects on mitochondrial morphology. Patient fibroblasts exhibit a fragmented mitochondrial network with swollen and irregularly shaped mitochondria showing partial to complete loss of cristae [jonckheere-2011-topology-abstract]. Complementation with wild-type TMEM70 can completely restore normal mitochondrial morphology [jonckheere-2011-topology-abstract]. In TMEM70 knockout mouse embryos, mitochondria display concentric or irregular cristae structures [vrbacky-2016-knockout-abstract]. Studies using immunogold electron microscopy and tomography have shown that mitochondrial DNA nucleoid clusters are disrupted in abnormal mitochondria from TMEM70-deficient patients, with both nucleoids and respiratory chain complexes confined to the outer rings of the cristae whorls [cameron-2010-nucleoid-abstract]. This observation may explain the differential effects on complex V expression and assembly in different tissues.

Metabolic Consequences

TMEM70 deficiency results in severely impaired mitochondrial ATP production. In patient fibroblasts, there is an 82-89% decrease in ATP synthase content [havlickova-2012-compensation-abstract]. This leads to decreased ADP-stimulated State 3 respiration, reduced respiratory control ratio, and lower ATP/ADP ratios [vrbacky-2016-knockout-abstract]. Interestingly, cells respond to ATP synthase deficiency with compensatory upregulation of other respiratory chain complexes: a 50-162% increase in Complex IV and a 22-53% increase in Complex III [havlickova-2012-compensation-abstract]. This compensation occurs through posttranscriptional mechanisms rather than changes in mRNA levels [havlickova-2012-compensation-abstract]. Additionally, diminished ATP synthase results in elevated mitochondrial membrane potential and increased reactive oxygen species (ROS) production [havlickova-2012-compensation-abstract].

Mouse Knockout Studies

Generation of Tmem70 knockout mice has provided critical insights into the essential nature of this protein. Homozygous Tmem70-/- knockouts exhibit profound growth retardation and embryonic lethality at approximately embryonic day 9.5 [vrbacky-2016-knockout-abstract]. Blue-Native electrophoresis demonstrates an 80% decrease in fully assembled ATP synthase and marked accumulation of F1 complexes, indicating that biogenesis is stalled following F1 oligomer formation [vrbacky-2016-knockout-abstract]. Heterozygous Tmem70+/- mice are fully viable and display normal postnatal growth, but they present with mild deterioration of heart function [vrbacky-2016-knockout-abstract]. Transgenic rescue experiments using rats have shown that restoration of TMEM70 to 16-49% of normal levels is sufficient for full biochemical complementation in liver and partial complementation in heart [markovic-2022-transgenic-abstract].

Clinical Manifestations of TMEM70 Mutations

Disease Phenotype

Mutations in TMEM70 cause a distinctive clinical syndrome characterized by neonatal mitochondrial encephalocardiomyopathy (OMIM 604273). The largest cohort study to date examined 48 patients and found neonatal onset in 85% of cases [magner-2015-longterm-abstract]. The most frequent presenting features include severe muscular hypotonia (92-95% of patients), apneic spells (92%), hypertrophic cardiomyopathy (76-89%), and profound lactic acidosis with lactate levels of 5-36 mmol/L (92%) [honzik-2010-natural-history-abstract][magner-2015-longterm-abstract]. Hyperammonemia (100-520 μmol/L) is present in 86% of cases and 3-methylglutaconic aciduria is a consistent finding [honzik-2010-natural-history-abstract]. Additional features include developmental delay (98%), faltering growth (94%), short stature (89%), microcephaly (71%), and facial dysmorphism (66%) [magner-2015-longterm-abstract]. Male patients frequently present with hypospadias (50-54%) and cryptorchidism (67%) [honzik-2010-natural-history-abstract]. Persistent pulmonary hypertension of the newborn has been identified as a life-threatening complication in 22% of patients [catteruccia-2014-pphn-abstract][magner-2015-longterm-abstract]. Notably, the cardiomyopathy is typically non-progressive and may even resolve in some children [honzik-2010-natural-history-abstract].

Genetic Basis

The most common mutation is a homozygous splice site mutation c.317-2A>G, which is particularly prevalent in the Roma population [cizkova-2008-discovery-abstract][magner-2015-longterm-abstract]. However, TMEM70 deficiency is a panethnic disease, and numerous other mutations have been identified in patients of various ethnic backgrounds including Arab Muslim and Turkish populations [magner-2015-longterm-abstract]. These include missense, frameshift, and other splice site mutations throughout the gene [spiegel-2011-commonmutations-abstract].

Metabolic Biomarkers and Classification

A hallmark metabolic feature of TMEM70 deficiency is elevated urinary 3-methylglutaconic acid (3-MGA), which places this disorder in the category of "secondary 3-methylglutaconic acidurias" [wortmann-2013-3mga-abstract]. Unlike primary 3-MGA-uria caused by defects in leucine catabolism (AUH deficiency), the 3-MGA elevation in TMEM70 deficiency arises from compromised mitochondrial membrane function. TMEM70 deficiency is classified alongside other mitochondrial membrane-associated disorders that present with 3-MGA-uria, including Costeff syndrome (OPA3 defect) and DCMA syndrome (DNAJC19 defect) [wortmann-2013-3mga-abstract]. This metabolic signature provides a useful diagnostic clue, as consistent and significant 3-MGA elevation in a neonate with encephalocardiomyopathy should prompt consideration of TMEM70 deficiency [wortmann-2013-3mga-abstract].

Prognosis and Management

The prognosis for TMEM70 deficiency is variable but serious. Ten-year survival is approximately 63%, with most deaths occurring in the neonatal period; importantly, no deaths have been reported after the age of five years in surviving patients [magner-2015-longterm-abstract]. Acute metabolic crises with life-threatening hyperammonemia can occur during childhood, often triggered by acute gastroenteritis and prolonged fasting [honzik-2010-natural-history-abstract]. These episodes respond to treatment with intravenous glucose and lipid infusion, ammonia scavengers, or hemodialfiltration [magner-2015-longterm-abstract]. Importantly, adequate management of hyperammonemic crises in the neonatal period and early childhood is critical for long-term outcomes [magner-2015-longterm-abstract].

Open Questions

Despite significant advances in understanding TMEM70 function, several important questions remain:

1. Precise molecular mechanism: While TMEM70 has been established as a scaffold for c-ring assembly, the exact molecular mechanism by which TMEM70 oligomers promote subunit c oligomerization remains unclear. Does TMEM70 actively catalyze c-ring formation or simply provide a permissive environment?

2. Coordination with other assembly factors: How does TMEM70 coordinate with other ATP synthase assembly factors such as the INA complex (Ina17/Ina22), which facilitates peripheral stalk assembly? What is the temporal sequence of these interactions during holoenzyme biogenesis?

3. Complex I involvement: The dual role of TMEM70 in both Complex I and Complex V assembly requires further elucidation. Does TMEM70 perform similar functions for both complexes, or are the mechanisms distinct?

4. TMEM186 and TMEM223 functions: The roles of the related family members TMEM186 and TMEM223 in mitochondrial biogenesis remain largely unexplored. Do these proteins have redundant or distinct functions?

5. Tissue-specific effects: Why do some tissues show more severe consequences of TMEM70 deficiency than others? The observation of differential effects on cristae structure and nucleoid organization across tissues deserves further investigation.

6. Therapeutic approaches: Can gene therapy or other interventions effectively treat TMEM70 deficiency? The transgenic rescue experiments in rats are encouraging but translation to clinical applications remains to be developed.

7. Structural biology: High-resolution structural information on TMEM70, particularly in complex with subunit c intermediates, would greatly enhance understanding of its molecular function.

References

1. cizkova-2008-discovery: Cízkova A, Stránecký V, Mayr JA, et al. TMEM70 mutations cause isolated ATP synthase deficiency and neonatal mitochondrial encephalocardiomyopathy. Nature Genetics. 2008;40(11):1288-90. PMID: 18953340. DOI: 10.1038/ng.246

2. bahri-2020-scaffold: Bahri H, Buratto J, Rojo M, et al. TMEM70 forms oligomeric scaffolds within mitochondrial cristae promoting in situ assembly of mammalian ATP synthase proton channel. Biochimica et Biophysica Acta - Molecular Cell Research. 2020;1868(4):118942. PMID: 33359711. DOI: 10.1016/j.bbamcr.2020.118942

3. kovalcikova-2019-subunitc: Kovalčíková J, Vrbacký M, Pecina P, et al. TMEM70 facilitates biogenesis of mammalian ATP synthase by promoting subunit c incorporation into the rotor structure of the enzyme. FASEB Journal. 2019;33(12):14103-14117. PMID: 31652072. DOI: 10.1096/fj.201900685RR

4. sanchez-caballero-2020-complexI: Sánchez-Caballero L, Elurbe DM, Baertling F, et al. TMEM70 functions in the assembly of complexes I and V. Biochimica et Biophysica Acta - Bioenergetics. 2020;1861(8):148202. PMID: 32275929. DOI: 10.1016/j.bbabio.2020.148202

5. houstek-2009-ancillary: Houstek J, Kmoch S, Zeman J. TMEM70 protein - a novel ancillary factor of mammalian ATP synthase. Biochimica et Biophysica Acta - Bioenergetics. 2009;1787(5):529-32. PMID: 19103153. DOI: 10.1016/j.bbabio.2008.11.013

6. jonckheere-2011-topology: Jonckheere AI, Huigsloot M, Lammens M, et al. Restoration of complex V deficiency caused by a novel deletion in the human TMEM70 gene normalizes mitochondrial morphology. Mitochondrion. 2011;11(6):954-63. PMID: 21945727. DOI: 10.1016/j.mito.2011.08.012

7. kratochvilova-2014-topology: Kratochvílová H, Hejzlarová K, Vrbacký M, et al. Mitochondrial membrane assembly of TMEM70 protein. Mitochondrion. 2014;15:1-9. PMID: 24576557. DOI: 10.1016/j.mito.2014.02.010

8. vrbacky-2016-knockout: Vrbacký M, Kovalčíková J, Chawengsaksophak K, et al. Knockout of Tmem70 alters biogenesis of ATP synthase and leads to embryonal lethality in mice. Human Molecular Genetics. 2016;25(21):4674-4685. PMID: 28173120. DOI: 10.1093/hmg/ddw295

9. honzik-2010-natural-history: Honzík T, Tesarová M, Mayr JA, et al. Mitochondrial encephalocardio-myopathy with early neonatal onset due to TMEM70 mutation. Archives of Disease in Childhood. 2010;95(4):296-301. PMID: 20335238. DOI: 10.1136/adc.2009.168096

10. magner-2015-longterm: Magner M, Dvorakova V, Tesarova M, et al. TMEM70 deficiency: long-term outcome of 48 patients. Journal of Inherited Metabolic Disease. 2015;38(3):417-26. PMID: 25326274. DOI: 10.1007/s10545-014-9774-8

11. torraco-2012-hotspot: Torraco A, Verrigni D, Rizza T, et al. TMEM70: a mutational hot spot in nuclear ATP synthase deficiency with a pivotal role in complex V biogenesis. Neurogenetics. 2012;13(4):375-86. PMID: 22986587. DOI: 10.1007/s10048-012-0343-8

12. cameron-2010-nucleoid: Cameron JM, Levandovskiy V, Mackay N, et al. Complex V TMEM70 deficiency results in mitochondrial nucleoid disorganization. Mitochondrion. 2010;11(1):191-9. PMID: 20920610. DOI: 10.1016/j.mito.2010.09.008

13. havlickova-2012-compensation: Havlíčková Karbanová V, Cížková Vrbacká A, Hejzlarová K, et al. Compensatory upregulation of respiratory chain complexes III and IV in isolated deficiency of ATP synthase due to TMEM70 mutation. Biochimica et Biophysica Acta - Bioenergetics. 2012;1817(7):1037-43. PMID: 22433607. DOI: 10.1016/j.bbabio.2012.03.004

14. tauchmannova-2024-review: Tauchmannová K, Pecinová A, Houštěk J, Mráček T. Variability of Clinical Phenotypes Caused by Isolated Defects of Mitochondrial ATP Synthase. Physiological Research. 2024;73(Suppl 1):S243-S278. PMID: 39016153. PMCID: PMC11412354. DOI: 10.33549/physiolres.935407

15. spiegel-2011-commonmutations: Spiegel R, Khayat M, Shalev SA, et al. TMEM70 mutations are a common cause of nuclear encoded ATP synthase assembly defect: further delineation of a new syndrome. Journal of Medical Genetics. 2011;48(3):177-82. PMID: 21147908. DOI: 10.1136/jmg.2010.084608

16. catteruccia-2014-pphn: Catteruccia M, Verrigni D, Martinelli D, et al. Persistent pulmonary arterial hypertension in the newborn (PPHN): a frequent manifestation of TMEM70 defective patients. Molecular Genetics and Metabolism. 2014;111(3):353-359. PMID: 24485043. DOI: 10.1016/j.ymgme.2014.01.001

17. markovic-2022-transgenic: Marković A, Tauchmannová K, Šimáková M, et al. Genetic Complementation of ATP Synthase Deficiency Due to Dysfunction of TMEM70 Assembly Factor in Rat. Biomedicines. 2022;10(2):276. PMID: 35203486. PMCID: PMC8869460. DOI: 10.3390/biomedicines10020276

18. diodato-2014-italian: Diodato D, Invernizzi F, Lamantea E, et al. Common and Novel TMEM70 Mutations in a Cohort of Italian Patients with Mitochondrial Encephalocardiomyopathy. JIMD Reports. 2014;15:71-8. PMID: 24740313. PMCID: PMC4270871. DOI: 10.1007/8904_2014_300

19. el-hattab-2016-cardiomyopathy: El-Hattab AW, Scaglia F. Mitochondrial Cardiomyopathies. Frontiers in Cardiovascular Medicine. 2016;3:25. PMID: 27504452. PMCID: PMC4958622. DOI: 10.3389/fcvm.2016.00025

20. carroll-2021-tmem242: Carroll J, He J, Ding S, Fearnley IM, Walker JE. TMEM70 and TMEM242 help to assemble the rotor ring of human ATP synthase and interact with assembly factors for complex I. Proceedings of the National Academy of Sciences USA. 2021;118(13):e2100558118. PMID: 33753518. PMCID: PMC8020751. DOI: 10.1073/pnas.2100558118

21. wortmann-2013-3mga: Wortmann SB, Duran M, Anikster Y, et al. Inborn errors of metabolism with 3-methylglutaconic aciduria as discriminative feature: proper classification and nomenclature. Journal of Inherited Metabolic Disease. 2013;36(6):923-8. PMID: 23296368. DOI: 10.1007/s10545-012-9580-0

22. zhou-2021-atpaf1: Zhou Z, Zhang K, Liu Z, et al. ATPAF1 deficiency impairs ATP synthase assembly and mitochondrial respiration. Mitochondrion. 2021;60:129-141. PMID: 34375736. PMCID: PMC9201681. DOI: 10.1016/j.mito.2021.08.005

Citations

1. bahri-2020-scaffold-abstract.md
2. cameron-2010-nucleoid-abstract.md
3. carroll-2021-tmem242-abstract.md
4. catteruccia-2014-pphn-abstract.md
5. cizkova-2008-discovery-abstract.md
6. diodato-2014-italian-abstract.md
7. havlickova-2012-compensation-abstract.md
8. honzik-2010-natural-history-abstract.md
9. houstek-2009-ancillary-abstract.md
10. jonckheere-2011-topology-abstract.md
11. kovalcikova-2019-subunitc-abstract.md
12. kratochvilova-2014-topology-abstract.md
13. magner-2015-longterm-abstract.md
14. markovic-2022-transgenic-abstract.md
15. sanchez-caballero-2020-complexI-abstract.md
16. spiegel-2011-commonmutations-abstract.md
17. tauchmannova-2024-review-abstract.md
18. torraco-2012-hotspot-abstract.md
19. vrbacky-2016-knockout-abstract.md
20. wortmann-2013-3mga-abstract.md
21. zhou-2021-atpaf1-abstract.md

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Plan and verification
- Identity verification: The target matches UniProt Q9BUB7: human TMEM70, a mitochondrial transmembrane protein in the TMEM70 family (PF06979). Recent literature describes TMEM70 as a two-pass inner-membrane protein with matrix-facing N- and C-termini, consistent with UniProt domain/family annotations and a role in ATP synthase biogenesis (see below) (markovic2023subunitcof pages 85-87, markovic2023subunitcof pages 7-10).

Comprehensive research report: TMEM70 (UniProt Q9BUB7)

1) Key concepts and definitions (current understanding)
- Gene/protein and localization: TMEM70 encodes an inner mitochondrial membrane protein of about 21 kDa with two transmembrane helices; both termini face the matrix, and a loop faces the intermembrane space (IMM topology deduced by proteomics and topology mapping). This topology situates TMEM70 to act on incoming substrates within the TIM23 import pathway at the IMM (markovic2023subunitcof pages 85-87).
- Molecular function: TMEM70 is an assembly factor of mitochondrial ATP synthase (Complex V), required for the membrane insertion and subsequent assembly of subunit c into the oligomeric c-ring. Loss of TMEM70 primarily reduces assembled ATP synthase with accumulation of the soluble F1 sector, indicating a biogenesis block on the Fo side (markovic2023subunitcof pages 7-10, markovic2023subunitcof pages 23-26).
- Mechanistic role in ATP synthase biogenesis: Experimental evidence supports that TMEM70 facilitates TIM23-dependent import and lateral insertion of the second transmembrane helix (TM2) of subunit c into the IMM; in the absence of TMEM70, a subunit c construct containing only TM2 fails to insert and is degraded. Mechanistic models also propose an oligomeric TMEM70 scaffold that organizes c-ring assembly before engagement with the F1 headpiece (markovic2023subunitcof pages 85-87, markovic2023subunitcof pages 7-10, markovic2023subunitcof pages 23-26).
- Interacting partners and pathway context: TMEM70 interacts with components of the TIM import machinery (e.g., TIMM44, TIMM21) and with TMEM242, another factor acting downstream to protect newly imported subunit c from degradation. Proteomic links to complex I assembly/maintenance (MCIA) have been reported, consistent with secondary complex I reductions upon TMEM70 loss (markovic2023subunitcof pages 85-87, markovic2023subunitcof pages 94-97).

2) Recent developments and latest research (2023–2024 focus)
- Mechanistic advances (2023): Mass-spectrometry and targeted interaction studies identified TMEM70 and TMEM242 among the top interactors of subunit c. TMEM70’s central role in inserting subunit c TM2 via the TIM23 pathway was supported by import/assembly assays; TMEM242 binds TMEM70 and likely acts downstream to stabilize c prior to c-ring assembly. C15orf61, identified in screens, does not contribute to ATP synthase assembly (markovic2023subunitcof pages 1-7, markovic2023subunitcof pages 7-10, markovic2023subunitcof pages 85-87).
- Quantitative assembly phenotypes: TMEM70 deficiency leads to a 60–70% decrease in assembled ATP synthase with concomitant F1 accumulation; TMEM242 depletion preferentially reduces assembled complex V and, in complete knockout, can also reduce complexes I and IV (markovic2023subunitcof pages 23-26, markovic2023subunitcof pages 7-10).
- Disease-oriented curation (2024): A systematic review (Aug 2024; Physiological Research; doi:10.33549/physiolres.935407; https://doi.org/10.33549/physiolres.935407) confirms TMEM70’s involvement in c8-ring assembly and F1 association, catalogues at least 20 pathogenic TMEM70 variants, and highlights that nuclear DNA variants account for ~60% (38/63) of variants in isolated ATP synthase deficiency, with TMEM70 representing the majority of nuclear cases (tauchmannova2024variabilityofclinical pages 3-5).
- Genotype–phenotype and markers (2024): Variant mapping shows clustering in the transit peptide/first transmembrane region, at the C-terminus, and at splice sites (including recurrent c.317–2A>G). Clinical markers that may aid early diagnosis include hyperammonemia and hypocitrullinemia in TMEM70 deficiency (tauchmannova2024variabilityofclinical pages 21-22).
- Therapeutic experimentation (2023): In inducible Tmem70 knockout mice, a ketogenic diet extended median survival, modestly increased assembled ATP synthase, and improved respiratory capacity; transgenic data indicate that very small amounts of TMEM70 suffice for full complementation of complex V content/function, supporting gene-therapy feasibility (markovic2023subunitcof pages 94-97, markovic2023subunitcof pages 1-7).

3) Applications and real-world implementations
- Diagnostics and variant interpretation: TMEM70 is established in diagnostic gene panels for mitochondrial disease and isolated ATP synthase deficiency, with biallelic autosomal inheritance patterns curated by platforms such as OpenTargets and clinical genetics resources (OpenTargets Search: -TMEM70). The 2024 review provides a consolidated reference for variant types and clinical suspicion markers that can guide exome/genome interpretation and biochemical screening (tauchmannova2024variabilityofclinical pages 3-5, tauchmannova2024variabilityofclinical pages 21-22).
- Biomarker-informed screening: Hyperammonemia and hypocitrullinemia may serve as supportive early markers in suspected TMEM70-related disease, informing follow-up genetic testing and metabolic management pathways (tauchmannova2024variabilityofclinical pages 21-22).
- Therapeutic strategies under consideration: Nutritional/metabolic modulation (e.g., ketogenic diet) showed preclinical benefit in murine inducible knockout models, motivating careful clinical consideration in selected contexts; the observation that minimal TMEM70 expression can restore ATP synthase supports gene-replacement concepts as longer-term strategies (markovic2023subunitcof pages 94-97, markovic2023subunitcof pages 1-7).

4) Expert opinions and analysis
- Assembly-factor centrality: Convergent evidence positions TMEM70 as the principal nuclear-encoded determinant of ATP synthase assembly among known assembly factors, particularly at the Fo subunit c insertion/c-ring assembly steps; TMEM242 likely assists downstream, while other candidates (e.g., C15orf61) do not appear essential. This hierarchy is consistent with the predominance of TMEM70 variants in human complex V deficiency cohorts (markovic2023subunitcof pages 7-10, markovic2023subunitcof pages 23-26, tauchmannova2024variabilityofclinical pages 3-5).
- Pathway spillover: The frequent secondary impact on complex I in TMEM70 deficiency suggests broader consequences for mitochondrial biogenesis/stability under stress or impaired complex V assembly, mirroring phenotypes seen with other mitochondrial chaperone/assembly disturbances (markovic2023subunitcof pages 94-97).
- Clinical spectrum and prognosis: TMEM70 deficiency presents as a severe neonatal/infantile encephalo-cardio-myopathy with frequent hypertrophic cardiomyopathy and metabolic crises; despite severity, survival into later childhood or beyond is possible in a subset, emphasizing the need for early recognition and supportive care (tauchmannova2024variabilityofclinical pages 21-22, markovic2023subunitcof pages 23-26).

5) Statistics and data from recent studies
- Variants and prevalence within ATP synthase defects: At least 20 pathogenic TMEM70 variants are recorded, with TMEM70 constituting the majority of nuclear-encoded isolated ATP synthase deficiencies; overall, nuclear DNA variants account for ~60% (38/63) of variants in isolated ATP synthase deficiency (Aug 2024 review; doi:10.33549/physiolres.935407) (tauchmannova2024variabilityofclinical pages 3-5).
- Family counts and clinical burden: >20 distinct mutations reported across ~50 families; hypertrophic cardiomyopathy prevalence ~93% in summarized cohorts; approximate 10-year survival ~63% (synthesis from Marković 2023 reporting) (markovic2023subunitcof pages 23-26).
- Quantitative assembly phenotype: Assembled ATP synthase is reduced by approximately 60–70% in TMEM70 deficiency, with accumulation of the F1 sector (markovic2023subunitcof pages 23-26).

6) Disease associations (structured resources)
- OpenTargets disease links: TMEM70 is strongly associated with mitochondrial encephalo-cardio-myopathy due to TMEM70 deficiency (Orphanet_1194), mitochondrial complex V (ATP synthase) deficiency, nuclear type 2 (MONDO_0013546), isolated ATP synthase deficiency (Orphanet_254913), and broader mitochondrial disease categories, with high association scores and evidence curated from Genomics England, Orphanet, EVA and literature; inheritance is biallelic autosomal (OpenTargets Platform; association scores ~0.59–0.85; multiple PMIDs) (OpenTargets Search: -TMEM70).

7) Domain/family alignment and cross-check
- TMEM70 belongs to the TMEM70 family and is predicted to be a two-pass IMM protein; recent experimental topology data match these predictions (matrix-oriented termini), aligning with UniProt domains and the provided family annotations (PF06979/IPR009724) (markovic2023subunitcof pages 85-87).

Open questions and future directions
- Structural mechanism: The precise structural basis for TMEM70’s assistance in TM2 lateral insertion and c-ring nucleation remains to be fully resolved; oligomerization state and transient complexes with subunit c and TMEM242 are priority targets for structural biology (markovic2023subunitcof pages 7-10, markovic2023subunitcof pages 23-26).
- Clinical translation: The preclinical benefits of ketogenic diet in murine models and the demonstration that very low TMEM70 rescues complex V content motivate evaluation of metabolic therapy protocols and gene-replacement approaches in carefully phenotyped patients (markovic2023subunitcof pages 94-97, markovic2023subunitcof pages 1-7).

Key summary table
| Category | Key findings | Quantitative data | Source (year) |
|---|---|---:|---|
| Identity & localization | Transmembrane protein 70 (TMEM70); localizes to inner mitochondrial membrane with matrix-oriented N‑ and C‑termini; predicted two transmembrane helices. | ~21 kDa; 2 TM helices; gene on chr8. | 2023 |
| Molecular function | ATP synthase (Complex V) assembly factor required for incorporation of subunit c and c‑ring formation; deficiency leads to loss of assembled CV and accumulation of F1. | Assembled CV decreased ~60–70%; F1 accumulation observed. | 2023–2024 |
| Specific mechanistic role | Facilitates TIM23‑dependent import / lateral insertion of subunit c TM2 into the inner membrane; may form an oligomeric scaffold for c‑ring assembly; TMEM242 acts downstream to protect subunit c from degradation. | TM2 fails to insert without TMEM70; TMEM242 knockdown lowers assembled CV; TMEM242 KO reduces CI and CIV. | 2023 |
| Interacting partners & pathway notes | Interacts with TIM complex components (e.g., TIMM44, TIMM21), TMEM242; proteomics links to MCIA / Complex I assembly pathways. | Identified among top interactors in mass‑spec/BioID screens. | 2023 |
| Disease associations & genotype–phenotype | Biallelic TMEM70 variants cause mitochondrial encephalo‑cardio‑myopathy: neonatal metabolic crises, hypertrophic cardiomyopathy, LV noncompaction, hypotonia; biochemical markers include hyperammonemia and hypocitrullinemia. | ≥20 pathogenic variants reported; ~50 families described; cardiac involvement ≈93% in cohorts; 10‑yr survival ≈63%. | 2023–2024 |
| Prevalence among ATP synthase defects | TMEM70 is the most frequent nuclear‑encoded cause of isolated ATP synthase deficiency. | Nuclear DNA accounts for ~60% (38/63) of variants in isolated ATP synthase deficiency; TMEM70 represents the majority of nDNA cases. | 2024 |
| Therapeutic & experimental insights | Animal models: transgenic complementation with low TMEM70 restores ATP synthase; inducible Tmem70 KO mice showed improved survival and assembled CV on a ketogenic diet; supports gene‑therapy and metabolic interventions. | Ketogenic diet extended median survival in iTmem70‑/- mice; very low TMEM70 expression sufficient for full complementation in transgenic models. | 2023 |

Table: Compact, evidence‑based summary of human TMEM70 (UniProt Q9BUB7) covering identity, molecular role in ATP synthase biogenesis, interactors, disease spectrum with quantitative facts, and experimental/therapeutic insights; useful as a quick reference for researchers and clinicians.

Cited sources with URLs/dates where available
- Tauchmannová K., Pecinová A., Houštěk J., Mrázek T. Variability of Clinical Phenotypes Caused by Isolated Defects of Mitochondrial ATP Synthase. Physiological Research. Aug 2024. doi:10.33549/physiolres.935407; https://doi.org/10.33549/physiolres.935407 (tauchmannova2024variabilityofclinical pages 3-5, tauchmannova2024variabilityofclinical pages 21-22).
- Marković A. Subunit c of mammalian F1Fo ATP synthase—from molecular mechanisms of assembly to potential therapies. 2023 (doctoral thesis/report; mechanistic and experimental insights; contains data on TMEM70/TMEM242 interactions and therapeutic models) (markovic2023subunitcof pages 85-87, markovic2023subunitcof pages 7-10, markovic2023subunitcof pages 23-26, markovic2023subunitcof pages 1-7, markovic2023subunitcof pages 94-97).
- OpenTargets Platform disease-association record for TMEM70 (ENSG00000175606). Accessed via platform evidence (association scores and curated inheritance; 2025 dataset release; specific PMIDs embedded in evidence) (OpenTargets Search: -TMEM70).

References

1. (markovic2023subunitcof pages 85-87): A Marković. Subunit c of mammalian f1fo atp synthase-from molecular mechanisms of assembly to potential therapies. Unknown journal, 2023.

2. (markovic2023subunitcof pages 7-10): A Marković. Subunit c of mammalian f1fo atp synthase-from molecular mechanisms of assembly to potential therapies. Unknown journal, 2023.

3. (markovic2023subunitcof pages 23-26): A Marković. Subunit c of mammalian f1fo atp synthase-from molecular mechanisms of assembly to potential therapies. Unknown journal, 2023.

4. (markovic2023subunitcof pages 94-97): A Marković. Subunit c of mammalian f1fo atp synthase-from molecular mechanisms of assembly to potential therapies. Unknown journal, 2023.

5. (markovic2023subunitcof pages 1-7): A Marković. Subunit c of mammalian f1fo atp synthase-from molecular mechanisms of assembly to potential therapies. Unknown journal, 2023.

6. (tauchmannova2024variabilityofclinical pages 3-5): K. Tauchmannová, A. Pecinová, J. Houštěk, and T. Mrázek. Variability of clinical phenotypes caused by isolated defects of mitochondrial atp synthase. Physiological Research, pages S243-S278, Aug 2024. URL: https://doi.org/10.33549/physiolres.935407, doi:10.33549/physiolres.935407. This article has 9 citations and is from a peer-reviewed journal.

7. (tauchmannova2024variabilityofclinical pages 21-22): K. Tauchmannová, A. Pecinová, J. Houštěk, and T. Mrázek. Variability of clinical phenotypes caused by isolated defects of mitochondrial atp synthase. Physiological Research, pages S243-S278, Aug 2024. URL: https://doi.org/10.33549/physiolres.935407, doi:10.33549/physiolres.935407. This article has 9 citations and is from a peer-reviewed journal.

8. (OpenTargets Search: -TMEM70): Open Targets Query (-TMEM70, 5 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

Citations

1. markovic2023subunitcof pages 85-87
2. tauchmannova2024variabilityofclinical pages 3-5
3. tauchmannova2024variabilityofclinical pages 21-22
4. markovic2023subunitcof pages 94-97
5. markovic2023subunitcof pages 23-26
6. markovic2023subunitcof pages 7-10
7. markovic2023subunitcof pages 1-7
8. https://doi.org/10.33549/physiolres.935407
9. https://doi.org/10.33549/physiolres.935407,

TMEM70: Functional Annotation and Recent Insights

Key Concepts and Current Understanding

Identity and Localization: TMEM70 (transmembrane protein 70) is a small nuclear-encoded protein (≈260 amino acids, ~29 kDa) that localizes to the mitochondrial inner membrane (pubmed.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). It is synthesized as a precursor with a mitochondrial targeting sequence, ensuring import into mitochondria. TMEM70 is part of a conserved family of membrane proteins (including TMEM186/TMEM223), but it is specifically found in higher eukaryotes and has no close analog in yeast (pmc.ncbi.nlm.nih.gov). Within mitochondria, TMEM70 predominantly resides in the cristae membranes – the folds of the inner membrane where respiratory complexes are concentrated (www.sciencedirect.com). Its topology includes multiple transmembrane segments, embedding it in the inner membrane to carry out its function in a local microenvironment distinct from general mitochondrial membranes (www.sciencedirect.com).

Role in ATP Synthase Biogenesis: TMEM70 is now recognized as an assembly factor for the mitochondrial ATP synthase (oxidative phosphorylation complex V). Unlike structural subunits of ATP synthase, assembly factors like TMEM70 do not form part of the final enzyme; instead, they assist in the proper construction of the multi-subunit complex. ATP synthase is the rotary enzyme that produces ATP using the proton gradient generated by respiration, and in humans it consists of 18 subunit types (~29 total subunits) organized into a catalytic F~1~ head and a membrane-embedded F~0~ domain (including a ring of c-subunits) (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). TMEM70’s specific role is to facilitate the assembly of the c-ring – the ring of 8 ATP synthase c-subunits that forms the proton-translocating rotor in the F~0~ domain (pmc.ncbi.nlm.nih.gov) (pubmed.ncbi.nlm.nih.gov). In the absence of functional TMEM70, the ATP synthase fails to incorporate the hydrophobic c-subunits, resulting in a stalled assembly: the F~1~ head and peripheral stalk are present, but the proton channel (F~0~) is incomplete, lacking the c-ring and associated subunit a (pubmed.ncbi.nlm.nih.gov). This incomplete complex is non-functional, as it cannot conduct protons or generate ATP. Thus, TMEM70 acts as a scaffolding factor that binds and stabilizes c-subunits during assembly, overcoming the otherwise low efficiency of spontaneous c-ring formation (pubmed.ncbi.nlm.nih.gov). It has been shown to physically interact with subunit c of ATP synthase, indicating a direct role in guiding these subunits into place (pubmed.ncbi.nlm.nih.gov). Researchers have described TMEM70 as a “specific ancillary factor for subunit c” – essentially a helper protein dedicated to building the c-subunit oligomer (pubmed.ncbi.nlm.nih.gov). Notably, TMEM70 is one of five known assembly factors required for mammalian ATP synthase biogenesis, and it is unique to metazoans (higher eukaryotes) (pmc.ncbi.nlm.nih.gov). Yeast rely on different factors for assembling their ATP synthase, and those yeast factors have no clear homologs in mammals (pmc.ncbi.nlm.nih.gov), underscoring that TMEM70 evolved to meet the assembly requirements in more complex organisms.

Biological Process and Pathway Context: By promoting ATP synthase assembly, TMEM70 is critical for oxidative phosphorylation (OXPHOS), the process by which cells generate ATP using the electron transport chain and ATP synthase. Proper ATP synthase assembly ensures efficient ATP production in tissues with high energy demand (brain, heart, skeletal muscle) (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). A functional ATP synthase is also important for maintaining the structure of mitochondrial cristae; indeed, fully assembled ATP synthase dimers help shape cristae membranes. When TMEM70 is defective and ATP synthase assembly is impaired, mitochondria exhibit disrupted cristae morphology (pmc.ncbi.nlm.nih.gov). For example, muscle biopsies from TMEM70-deficient patients show severe loss or disorganization of cristae structure (pmc.ncbi.nlm.nih.gov). This structural disruption can secondarily affect other respiratory chain complexes: studies found that TMEM70-mutant cells, besides lacking complex V, often have reductions in complexes I and IV activities, likely because cristae architecture is compromised (pmc.ncbi.nlm.nih.gov). Therefore, while TMEM70’s primary role is in Complex V assembly, its loss has a ripple effect on the entire OXPHOS system. There is also emerging evidence of crosstalk between ATP synthase assembly factors and Complex I assembly. Recent findings showed TMEM70 can interact with the MCIA complex (a mitochondrial complex I assembly machinery), suggesting TMEM70 might also assist or coordinate aspects of Complex I biogenesis (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). This link is still being clarified, but it hints that TMEM70’s function might integrate into broader mitochondrial assembly networks, potentially explaining why some TMEM70-deficient patients show multi-complex impairment.

In summary, under normal conditions TMEM70 operates in the mitochondrial inner membrane to ensure the efficient assembly of the ATP synthase F~0~ rotor (c-ring), thereby safeguarding cellular energy production. It is a non-enzymatic facilitator of ATP synthase biogenesis – indispensable for building a functional ATP-generating machinery inside human mitochondria (pmc.ncbi.nlm.nih.gov) (pubmed.ncbi.nlm.nih.gov).

Recent Developments and Latest Research (2021–2024)

Mechanistic Discoveries: Our understanding of TMEM70’s function remained speculative until the late 2010s, but several key studies have since provided clarity. In 2019, a conditional knockout mouse study demonstrated exactly how TMEM70 affects ATP synthase assembly: without TMEM70, mice accumulated the F~1~-domain subcomplex but could not form the c-ring or attach the membrane F~0~ domain, definitively proving TMEM70 is required to insert subunit c into the enzyme’s rotor structure (pubmed.ncbi.nlm.nih.gov). Building on this, researchers in 2021 identified an additional assembly factor, TMEM242, that works alongside TMEM70 for rotor assembly (pmc.ncbi.nlm.nih.gov). In a 2021 PNAS report (Carroll et al., 2021), John Walker’s group showed that human ATP synthase requires both TMEM70 and TMEM242 to assemble the c₈-ring of c-subunits (pmc.ncbi.nlm.nih.gov). They found that TMEM70 directly binds subunit c, and TMEM242 was newly shown to do likewise – providing a missing piece of the assembly puzzle. Intriguingly, the same study noted that TMEM70 and TMEM242 physically associate with a Complex I assembly scaffold (the MCIA complex), hinting that these factors might have dual roles or a coordinated function in assembling multiple mitochondrial complexes (pmc.ncbi.nlm.nih.gov). This discovery in 2021 broadened our view of TMEM70 from a single-complex helper to a potentially more integrative factor in mitochondrial biogenesis.

Assembly Mechanism – In Situ Insights: Another breakthrough came from advanced imaging and biochemical analysis of TMEM70’s behavior in cells. A 2021 study by Kovalčíková et al. used immunoprecipitation, native gel electrophoresis, and super-resolution microscopy to visualize how TMEM70 operates (www.sciencedirect.com). They found that TMEM70 molecules form large oligomeric complexes in the inner membrane that serve as a scaffold for c-ring assembly (www.sciencedirect.com). Free c-subunits (not yet part of ATP synthase) were shown to bind these TMEM70 oligomers, and intermediate-sized TMEM70–subunit c assemblies could be detected, indicating that TMEM70 oligomers gradually gather multiple c-subunits to build the complete ring (www.sciencedirect.com). This was a crucial insight into the stepwise assembly process. Additionally, using expansion microscopy, the authors pinpointed TMEM70’s location to discrete foci within the cristae membrane (away from junctional complexes like MICOS), suggesting that ATP synthase assembly occurs at specific cristae sites where TMEM70 concentrates (www.sciencedirect.com). Taken together, these findings updated the model of ATP synthase biogenesis: TMEM70 acts as an oligomeric platform within mitochondria to nucleate and grow the proton-conducting c-ring, ensuring efficient and timely assembly of the ATP synthase F~0~ sector (www.sciencedirect.com).

Therapeutic Advances – Gene Complementation: On the clinical research front, recent developments have explored ways to rescue TMEM70 deficiency, given its often devastating consequences. In 2022, a team led by Mráček et al. demonstrated a form of gene therapy in an animal model (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). They created a knockout rat (in which the Tmem70 gene was inactivated) – normally, such rats die embryonically, mirroring the critical role of TMEM70 in development (pmc.ncbi.nlm.nih.gov). The researchers then introduced a transgenic copy of the TMEM70 gene under a universal promoter in these rats. Remarkably, the transgene “rescued” the lethal phenotype: rats carrying the TMEM70 transgene were born alive and grew normally with only minor impairments (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Importantly, the amount of TMEM70 protein restored in tissues was only about 16–49% of normal levels, yet this was sufficient to fully restore ATP synthase assembly and mitochondrial function in most tissues (pmc.ncbi.nlm.nih.gov). In heart tissue (which has very high energy demands), the partial restoration led to only slight residual deficits in ATP synthase and a mild cardiac dysfunction, but even there the rats survived (pmc.ncbi.nlm.nih.gov). This study provided a proof-of-principle that even modest expression of TMEM70 can prevent the fatal outcome of its loss, paving the way for potential gene replacement therapies in humans (pmc.ncbi.nlm.nih.gov). It represents a significant development, showing successful genetic complementation of an otherwise fatal mitochondrial disorder (pmc.ncbi.nlm.nih.gov). While not yet in the clinic, this 2022 finding gives hope that TMEM70-deficient patients might benefit from future gene therapy or mRNA therapy approaches to supply functional TMEM70.

Ongoing and 2023–2024 Research: As of 2023, research on TMEM70 continues to advance in both basic and translational domains. Structural biologists are interested in capturing cryo-EM snapshots of ATP synthase assembly intermediates – for example, identifying whether TMEM70 or TMEM242 can be visualized in association with assembling ATP synthase modules. Such studies could emerge in late 2023 or 2024, building on the foundation from 2021. In parallel, clinical researchers are refining management of TMEM70 deficiency and identifying new patient mutations. While no brand-new TMEM70-specific therapies were approved as of 2024, the field is moving toward personalized interventions. The demonstration in a rat model in 2022 and accumulating knowledge of TMEM70’s mechanism will be crucial stepping stones for any future therapeutic trials (e.g. neonatal gene therapy or enzyme replacement strategies). Additionally, improved genomic sequencing in recent years has allowed faster diagnosis of TMEM70 mutations in infants with unexplained lactic acidosis, and 2023 case reports continue to broaden the mutational and phenotypic spectrum (for instance, novel mutations being linked to atypical features like congenital cataracts in some cases (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov)). The latest research therefore not only deepens our biochemical understanding of how TMEM70 facilitates energy production, but also directly informs clinical practice and therapeutic development.

Current Applications and Real-World Implementations

Clinical Diagnostics: Knowledge of TMEM70’s role has been applied in medical genetics and newborn medicine. TMEM70 mutations are now recognized as the most frequent cause of nuclear-encoded ATP synthase deficiency in humans (pmc.ncbi.nlm.nih.gov). Therefore, genetic testing for TMEM70 mutations is routinely included when infants present with clinical signs of a mitochondrial disorder—particularly a clinical profile of neonatal mitochondrial encephalocardiomyopathy, which is the hallmark syndrome caused by TMEM70 defects (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Since the gene’s identification in 2008–2009, many diagnostic laboratories worldwide have developed PCR and sequencing assays for TMEM70. This allows early confirmation of the diagnosis, often within the first weeks of life, enabling timely medical interventions. In certain populations, testing for a founder mutation can expedite diagnosis: for example, a splice-site mutation in intron 2 (c.317-2A>G) in TMEM70 has been found at high frequency in patients of Roma (Gypsy) ancestry (pmc.ncbi.nlm.nih.gov) (pubmed.ncbi.nlm.nih.gov). In a European cohort of 48 patients, 35 individuals (including 27 Roma patients) were homozygous for this single mutation (pubmed.ncbi.nlm.nih.gov). Such findings have led to population-specific diagnostic panels and even consideration of carrier screening in high-risk communities. The rapid identification of TMEM70 deficiency in a sick neonate is critical because it opens the possibility for targeted management (as opposed to diagnostic odysseys or inappropriate treatments).

Management and Therapy: Although there is currently no cure for TMEM70 deficiency, supportive metabolic therapy has proven life-saving in many cases. The condition often presents with severe lactic acidosis, hyperammonemia, and energy failure, which can be exacerbated by fasting or illness. As a result, a cornerstone of management is to avoid catabolic stress and ensure a continuous energy supply. During acute metabolic crises, physicians implement measures to shift the patient from a catabolic to an anabolic state (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). This includes providing alternative fuel substrates that bypass the blocked oxidative phosphorylation as much as possible: for example, high-dose intravenous glucose (to reduce reliance on fatty acid oxidation) is given, but since excessive glucose can worsen lactic acidosis, it is paired with lipid emulsions and amino acids as non-carbohydrate energy sources (pmc.ncbi.nlm.nih.gov). Such an “anaplerotic diet” approach — supplying protein and fat calories — has been used to mitigate energy deficits (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Alongside acute management, patients are often placed on chronic supplemental therapies aimed at bolstering mitochondrial function. These may include cofactors and antioxidants such as coenzyme Q₁₀, L-carnitine, riboflavin, thiamine, and lipoic acid, as well as vitamins E and C (pmc.ncbi.nlm.nih.gov). While formal trials are lacking, clinicians have reported anecdotal benefits or at least no harm from these supplements (pmc.ncbi.nlm.nih.gov). Notably, episodes of hyperammonemia (due to secondary urea cycle impairment during crises) can be effectively treated with standard measures like ammonia scavenger drugs or hemodialysis, often resulting in recovery from the immediate crisis (pmc.ncbi.nlm.nih.gov) (pubmed.ncbi.nlm.nih.gov).

With early supportive treatment, some patients show significant improvements. Cardiac symptoms (cardiomyopathy and heart failure) in TMEM70-deficient infants have been managed with standard heart failure therapies plus the above metabolic interventions, sometimes leading to stabilization of cardiac function (pmc.ncbi.nlm.nih.gov) (pubmed.ncbi.nlm.nih.gov). Remarkably, it has been observed that if an affected child survives beyond infancy, their long-term outlook improves substantially. An international study reported a 63% survival to 10 years of age, and notably no patient died after age 5 in that cohort (pubmed.ncbi.nlm.nih.gov). This suggests that the high early mortality can be overcome with diligent care, and those who adapt past a certain age may have a relatively stable course. Surviving children often still have lifelong disabilities – most have severe developmental delays, hypotonia, and require feeding support – but reaching childhood and adolescence was once unheard of for this condition and is now achievable (pubmed.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). These real-world outcomes underscore that TMEM70 deficiency is “amenable to treatment,” in the words of one case report, meaning that dedicated management can significantly alter the prognosis (pmc.ncbi.nlm.nih.gov).

Implications for Genetic Counseling and Future Therapies: The identification of TMEM70 also allows for genetic counseling of families. Parents of an affected child (who are carriers of a TMEM70 mutation) can be offered prenatal diagnosis or IVF with preimplantation genetic testing in subsequent pregnancies. In communities with common TMEM70 mutations, carrier screening programs are being considered to prevent cases through informed family planning (pmc.ncbi.nlm.nih.gov). On the horizon, the successful rat gene-rescue experiment (2022) has opened discussions about human gene therapy. While translating this to patients is complex (delivery to mitochondria, safety, etc.), it provides a real-world proof-of-concept that replacing a missing TMEM70 gene can cure the biochemical defect (pmc.ncbi.nlm.nih.gov). Researchers are exploring viral vectors or mRNA delivery targeted to mitochondria as potential future applications. In summary, current interventions revolve around metabolic support, but emerging strategies – from advanced nutrient therapies to gene replacement – are direct extensions of the fundamental knowledge about TMEM70’s function.

Expert Opinions and Analysis from Authoritative Sources

Mitochondrial experts emphasize the critical importance of TMEM70 in cellular energy metabolism. For instance, Dr. John E. Walker (a co-discoverer of ATP synthase’s rotary mechanism) and colleagues noted in 2021 that assembling the human ATP synthase is a modular process requiring accessory factors at specific steps. They highlight that TMEM70 is absolutely required for building the c-ring module, underscoring that without TMEM70, the ATP synthase cannot complete its rotor and ATP production is fatally compromised (pmc.ncbi.nlm.nih.gov). In the PNAS 2021 study, the authors wrote: “The assembly of the c₈-ring requires the participation of two membrane-associated proteins, TMEM70 and, as we demonstrate, TMEM242.” (pmc.ncbi.nlm.nih.gov). This authoritative statement encapsulates the now well-accepted view that TMEM70 is a linchpin in the assembly line of one of biology’s most important enzymes.

Another expert analysis comes from Kovalčíková et al. (2021), who delved into TMEM70’s mechanism. They concluded that “TMEM70 oligomers provide a scaffold for c-ring assembly and that mammalian ATP synthase is assembled within inner cristae membranes.” (www.sciencedirect.com). This insight, published in Biochimica et Biophysica Acta, was foundational in explaining how and where TMEM70 works. It shifted the perspective from viewing TMEM70 as just an auxiliary protein to seeing it as an active structural organizer in the confined space of cristae. The authors also described TMEM70 as an “ancillary factor for subunit c” that increases the otherwise low efficacy of spontaneous c-ring formation (pubmed.ncbi.nlm.nih.gov) – effectively, an expert acknowledgment that without TMEM70, cells likely could not assemble the ATP synthase fast enough to meet energy demands. In their discussion, they compare the assisted assembly to an unassisted scenario, noting that TMEM70’s presence prevents the accumulation of misassembled or free subunits and streamlines the biogenesis of the complex (pubmed.ncbi.nlm.nih.gov) (pubmed.ncbi.nlm.nih.gov).

Clinical experts have also weighed in. Magner et al., who reported the largest patient series to date, emphasized that TMEM70 mutations, despite causing almost complete ATP synthase deficiency, can be survived with proper care (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Their analysis of 48 cases identified common clinical patterns and led to management guidelines (e.g. the use of moderate glucose with alternative energy substrates during crises) (pmc.ncbi.nlm.nih.gov). They noted the surprising observation that no child with TMEM70 deficiency died after the age of five in their cohort, calling this “important for prognostication” and family counseling (pubmed.ncbi.nlm.nih.gov). This expert perspective shifted the narrative from an invariably fatal infantile disease to a condition that, while severe, has a treatable component and a window for intervention (pmc.ncbi.nlm.nih.gov). Several metabolic physicians have since echoed these points in reviews, often citing TMEM70 deficiency as an example of a mitochondrial disorder where early diagnosis and support can change outcomes. For example, Braczynski et al. (2015) noted that “TMEM70 mutations can cause [an] almost complete deficiency of ATP synthase but are still amenable to treatment.” (pmc.ncbi.nlm.nih.gov). This commentary, coming just a few years after the gene’s discovery, encapsulated optimism in the field – a sentiment that has grown stronger with subsequent expert analyses.

Finally, from a broad bioenergetics viewpoint, TMEM70’s discovery resolved a long-standing “unknown” in mitochondrial biology. Previously, assembly factors for the F~1~ (head) sector of ATP synthase were known (ATP11, ATP12), but it was uncertain how the membrane sector assembled. In 2013, Walker referred to the assembly of the ATP synthase’s membrane portion as one of the uncertain areas in the field (pubmed.ncbi.nlm.nih.gov). By 2021, authoritative sources could definitively state that TMEM70 (with TMEM242) fills that gap in knowledge (pmc.ncbi.nlm.nih.gov). In summary, expert consensus now holds TMEM70 as an essential component of mitochondrial biogenesis, and analyses from leaders in the field consistently underscore its dual significance: scientifically, as a key to understanding ATP synthase assembly, and medically, as a critical factor in a severe yet treatable metabolic disorder.

Relevant Statistics and Data from Recent Studies

• Prevalence of TMEM70 Deficiency: Since its identification, TMEM70 mutations have emerged as a leading cause of mitochondrial disease in newborns. By 2015, at least 65 patients with genetically confirmed TMEM70 deficiency had been reported worldwide (pmc.ncbi.nlm.nih.gov). It is now understood to be the most frequent nuclear gene cause of isolated ATP synthase (Complex V) deficiency (pmc.ncbi.nlm.nih.gov), accounting for a significant fraction of neonatal-onset mitochondrial encephalocardiomyopathies. Many cases occur in populations with higher rates of consanguinity. For example, over half of the known patients in one long-term outcome study were of Roma descent, all carrying the same founder mutation (c.317-2A>G) in homozygosity (pubmed.ncbi.nlm.nih.gov). This single mutation alone is responsible for an estimated 70%+ of TMEM70 disease alleles in Europe (pubmed.ncbi.nlm.nih.gov). Other mutations (missense, frameshift, etc.) are rarer and often family-specific, though new variants continue to be documented (including a recent novel mutation identified in an Italian cohort) (pmc.ncbi.nlm.nih.gov).

• Age of Onset and Survival: TMEM70-deficiency almost always manifests in the neonatal period. In a study of 48 affected individuals, 85% presented symptoms at or shortly after birth (pubmed.ncbi.nlm.nih.gov). (A few milder cases had onset in later infancy, and only one outlier case presented at 2 years (pubmed.ncbi.nlm.nih.gov).) Without intervention, the neonatal mortality is very high, but with modern supportive care the survival curve has improved. The 10-year survival was 63% in the aforementioned cohort (pubmed.ncbi.nlm.nih.gov). Notably, all deaths occurred in early childhood; no child who survived beyond 5 years of age died thereafter in that study (pubmed.ncbi.nlm.nih.gov). This suggests a bimodal outcome: either infants succumb early (during metabolic crises and heart failure of the first years), or if they can be stabilized past a critical period, they often reach a steadier state allowing longer-term survival. The oldest known TMEM70-deficient patient reported in that series was 17 years old (pmc.ncbi.nlm.nih.gov), demonstrating that survival into adolescence is possible.

• Clinical Features Frequency: TMEM70 deficiency causes a multi-system syndrome, and recent data quantify how consistently certain features appear. Almost all patients have profound muscle hypotonia (reduced muscle tone) – reported in 95% of cases (pubmed.ncbi.nlm.nih.gov). Developmental delay or neurodevelopmental impairment was noted in 98% of surviving patients, indicating the universal impact on the brain (pubmed.ncbi.nlm.nih.gov). The heart is another major target: hypertrophic cardiomyopathy (thickened, weakened heart muscle) was present in about 89% of patients (pubmed.ncbi.nlm.nih.gov), often leading to heart failure in infancy. Growth failure (failure to thrive) is extremely common (~94%), and about 89% also had short stature in the long term (pubmed.ncbi.nlm.nih.gov). Other notable findings include microcephaly (small head size) in ~71% and dysmorphic facial features (distinct facial dysmorphology) in ~66% (pubmed.ncbi.nlm.nih.gov). A unique observation was that among male patients, 50% had hypospadias (a genital anomaly), a frequency much higher than in the general population, though the link between TMEM70 and genital development remains unclear (pubmed.ncbi.nlm.nih.gov). In the neonatal period, persistent pulmonary hypertension was reported in about 22% of cases – this is a serious lung vascular condition that can complicate the metabolic and cardiac issues (pubmed.ncbi.nlm.nih.gov). Additionally, ~13% had Wolff-Parkinson-White syndrome, a specific cardiac conduction abnormality (pubmed.ncbi.nlm.nih.gov). These statistics, drawn from the largest patient aggregates, help physicians anticipate and monitor the myriad of complications in TMEM70-deficient infants.

• Biochemical Markers: From a laboratory perspective, TMEM70 disease is characterized by certain metabolic markers. Virtually all patients exhibit lactic acidemia (high lactate in blood) from birth due to impaired aerobic ATP production (pmc.ncbi.nlm.nih.gov). Another hallmark is 3-methylglutaconic aciduria, an elevated urine organic acid that was observed in the majority of patients (pubmed.ncbi.nlm.nih.gov). This metabolite is associated with mitochondrial dysfunction (it is also seen in a few other disorders affecting mitochondrial cristae structure). Hyperammonemia (elevated blood ammonia) is also common during decompensations, reflecting secondary liver/urea cycle stress; however, as noted, these episodes often respond to intravenous glucose and lipid with ammonia-scavenging drugs (pubmed.ncbi.nlm.nih.gov). Enzymatically, patient muscle or fibroblast samples show isolated complex V activity loss (often >90% deficiency of ATP synthase activity) with normal or near-normal activities of complexes I–IV (pmc.ncbi.nlm.nih.gov). Blue-native PAGE analysis confirms a near-absence of assembled ATP synthase complexes in patient tissues (pmc.ncbi.nlm.nih.gov). Interestingly, in fibroblasts some intermediate sub-assemblies of ATP synthase can accumulate, reflecting stalled assembly attempts (pmc.ncbi.nlm.nih.gov). These biochemical data solidify that TMEM70 mutations chiefly affect complex V, distinguishing this condition from other mitochondrial disorders that might have combined respiratory chain defects.

• Animal Model Data: Quantitative data from model organisms further emphasize TMEM70’s importance. Knockout mice for Tmem70 are embryonically lethal, indicating that complete loss of TMEM70 is incompatible with development (no live-born homozygous knockouts were obtained in a 2016 study) (pubmed.ncbi.nlm.nih.gov). The 2022 transgenic rescue rat model provided numbers on how much TMEM70 is “enough”: restoring 16–49% of normal TMEM70 levels in tissues was sufficient to fully normalize ATP synthase content and ATP production in most organs (pmc.ncbi.nlm.nih.gov). In heart muscle, ~20% of normal TMEM70 led to a partially lower ATP synthase level (with a minor decrease in cardiac function), whereas >40% largely corrected the defect (pmc.ncbi.nlm.nih.gov). This dosage effect data suggests there is a threshold of TMEM70 needed (likely around 10–20% of normal levels) to assemble enough ATP synthase to sustain basic survival, and higher levels further improve tissue function. Such findings are encouraging, as they imply that even incomplete therapies restoring a fraction of TMEM70 activity could substantially benefit patients.

Overall, these statistics and data points paint a clearer picture of TMEM70-related disease: it is rare but relatively prevalent among mitochondrial disorders, almost uniformly severe at birth, yet variably survivable with intervention. The quantitative benchmarks – from survival rates to percentage of enzyme restored – are invaluable for clinicians and researchers setting expectations and goals for treatment in this currently intractable genetic disease.

Citations

1. AnnotationURLCitation(end_index=443, start_index=276, title='TMEM70 facilitates biogenesis of mammalian ATP synthase by promoting subunit c incorporation into the rotor structure of the enzyme - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/31652072/#:~:text=provision%2C%20depends%20on%20transmembrane%20protein,o%7D%20proton%20channel%20composed')
2. AnnotationURLCitation(end_index=603, start_index=444, title='ATP Synthase Deficiency due to TMEM70 Mutation Leads to Ultrastructural Mitochondrial Degeneration and Is Amenable to Treatment - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4621340/#:~:text=description%20in%202008,with%20different%20genetically%20confirmed%20TMEM70')
3. AnnotationURLCitation(end_index=1009, start_index=884, title='Genetic Complementation of ATP Synthase Deficiency Due to Dysfunction of TMEM70 Assembly Factor in Rat - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8869460/#:~:text=one%E2%80%94c7orf55%20,CI%29%20biogenesis')
4. AnnotationURLCitation(end_index=1355, start_index=1169, title='TMEM70 forms oligomeric scaffolds within mitochondrial cristae promoting in situ assembly of mammalian ATP synthase proton channel - ScienceDirect', type='url_citation', url='https://www.sciencedirect.com/science/article/pii/S0167488920303001#:~:text=complexes%20with%20increasing%20Su,assembled%20within%20inner%20cristae%20membranes')
5. AnnotationURLCitation(end_index=1733, start_index=1547, title='TMEM70 forms oligomeric scaffolds within mitochondrial cristae promoting in situ assembly of mammalian ATP synthase proton channel - ScienceDirect', type='url_citation', url='https://www.sciencedirect.com/science/article/pii/S0167488920303001#:~:text=demonstrate%20using%20expansion%20super,mammalian%20ATP%20synthase%20is%20assembled')
6. AnnotationURLCitation(end_index=2527, start_index=2365, title='TMEM70 and TMEM242 help to assemble the rotor ring of human ATP synthase and interact with assembly factors for complex I - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8020751/#:~:text=membrane%20domain%20of%20the%20ATP,and%2C%20as%20we%20demonstrate%2C%20TMEM242')
7. AnnotationURLCitation(end_index=2681, start_index=2528, title='TMEM70 and TMEM242 help to assemble the rotor ring of human ATP synthase and interact with assembly factors for complex I - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8020751/#:~:text=The%20ATP%20synthase%20in%20human,arranged%20in%20long%20rows%20along')
8. AnnotationURLCitation(end_index=3027, start_index=2859, title='TMEM70 and TMEM242 help to assemble the rotor ring of human ATP synthase and interact with assembly factors for complex I - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8020751/#:~:text=organellar%20membrane%20of%20human%20ATP,and%2C%20as%20we%20demonstrate%2C%20TMEM242')
9. AnnotationURLCitation(end_index=3173, start_index=3028, title='TMEM70 facilitates biogenesis of mammalian ATP synthase by promoting subunit c incorporation into the rotor structure of the enzyme - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/31652072/#:~:text=TMEM70%20remains%20unknown,deficient%20cells.%20Altogether%2C%20we')
10. AnnotationURLCitation(end_index=3597, start_index=3452, title='TMEM70 facilitates biogenesis of mammalian ATP synthase by promoting subunit c incorporation into the rotor structure of the enzyme - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/31652072/#:~:text=TMEM70%20remains%20unknown,deficient%20cells.%20Altogether%2C%20we')
11. AnnotationURLCitation(end_index=3988, start_index=3860, title='TMEM70 facilitates biogenesis of mammalian ATP synthase by promoting subunit c incorporation into the rotor structure of the enzyme - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/31652072/#:~:text=of%20F_,spontaneous%20assembly%20of%20subunit%20c')
12. AnnotationURLCitation(end_index=4253, start_index=4125, title='TMEM70 facilitates biogenesis of mammalian ATP synthase by promoting subunit c incorporation into the rotor structure of the enzyme - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/31652072/#:~:text=of%20F_,spontaneous%20assembly%20of%20subunit%20c')
13. AnnotationURLCitation(end_index=4542, start_index=4414, title='TMEM70 facilitates biogenesis of mammalian ATP synthase by promoting subunit c incorporation into the rotor structure of the enzyme - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/31652072/#:~:text=of%20F_,spontaneous%20assembly%20of%20subunit%20c')
14. AnnotationURLCitation(end_index=4847, start_index=4700, title='Genetic Complementation of ATP Synthase Deficiency Due to Dysfunction of TMEM70 Assembly Factor in Rat - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8869460/#:~:text=Five%20assembly%20factors%20have%20been,Most%20recently%2C%20an')
15. AnnotationURLCitation(end_index=5113, start_index=4974, title='Genetic Complementation of ATP Synthase Deficiency Due to Dysfunction of TMEM70 Assembly Factor in Rat - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8869460/#:~:text=factors%20are%20involved%20in%20the,and%20we%20recently')
16. AnnotationURLCitation(end_index=5747, start_index=5577, title='Genetic Complementation of ATP Synthase Deficiency Due to Dysfunction of TMEM70 Assembly Factor in Rat - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8869460/#:~:text=Mutations%20of%20the%20TMEM70%20gene,Tmem70%5E%7Bko%7D%5E%7B%2Fko%7D%20knockout%20rats')
17. AnnotationURLCitation(end_index=5945, start_index=5748, title='Genetic Complementation of ATP Synthase Deficiency Due to Dysfunction of TMEM70 Assembly Factor in Rat - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8869460/#:~:text=Mitochondrial%20diseases%20represent%20deleterious%20disorders,onset%20mitochondrial%20diseases%2C%20where%20they')
18. AnnotationURLCitation(end_index=6401, start_index=6239, title='Common and Novel TMEM70 Mutations in a Cohort of Italian Patients with Mitochondrial Encephalocardiomyopathy - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4270871/#:~:text=accumulation%20of%20sub,disrupting%20the%20mitochondrial%20cristae%20structure')
19. AnnotationURLCitation(end_index=6682, start_index=6520, title='Common and Novel TMEM70 Mutations in a Cohort of Italian Patients with Mitochondrial Encephalocardiomyopathy - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4270871/#:~:text=accumulation%20of%20sub,disrupting%20the%20mitochondrial%20cristae%20structure')
20. AnnotationURLCitation(end_index=7109, start_index=6947, title='Common and Novel TMEM70 Mutations in a Cohort of Italian Patients with Mitochondrial Encephalocardiomyopathy - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4270871/#:~:text=accumulation%20of%20sub,disrupting%20the%20mitochondrial%20cristae%20structure')
21. AnnotationURLCitation(end_index=7699, start_index=7540, title='TMEM70 and TMEM242 help to assemble the rotor ring of human ATP synthase and interact with assembly factors for complex I - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8020751/#:~:text=complexes%20I%2C%20III%2C%20and%20IV,the%20regulation%20of%20their%20levels')
22. AnnotationURLCitation(end_index=7879, start_index=7700, title='Genetic Complementation of ATP Synthase Deficiency Due to Dysfunction of TMEM70 Assembly Factor in Rat - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8869460/#:~:text=deciphered%20its%20molecular%20role%20in,spectrum%20of%20potential%20phenotypic%20presentations')
23. AnnotationURLCitation(end_index=8649, start_index=8479, title='Genetic Complementation of ATP Synthase Deficiency Due to Dysfunction of TMEM70 Assembly Factor in Rat - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8869460/#:~:text=Mutations%20of%20the%20TMEM70%20gene,Tmem70%5E%7Bko%7D%5E%7B%2Fko%7D%20knockout%20rats')
24. AnnotationURLCitation(end_index=8795, start_index=8650, title='TMEM70 facilitates biogenesis of mammalian ATP synthase by promoting subunit c incorporation into the rotor structure of the enzyme - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/31652072/#:~:text=TMEM70%20remains%20unknown,deficient%20cells.%20Altogether%2C%20we')
25. AnnotationURLCitation(end_index=9495, start_index=9350, title='TMEM70 facilitates biogenesis of mammalian ATP synthase by promoting subunit c incorporation into the rotor structure of the enzyme - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/31652072/#:~:text=TMEM70%20remains%20unknown,deficient%20cells.%20Altogether%2C%20we')
26. AnnotationURLCitation(end_index=9807, start_index=9639, title='TMEM70 and TMEM242 help to assemble the rotor ring of human ATP synthase and interact with assembly factors for complex I - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8020751/#:~:text=organellar%20membrane%20of%20human%20ATP,and%2C%20as%20we%20demonstrate%2C%20TMEM242')
27. AnnotationURLCitation(end_index=10162, start_index=9994, title='TMEM70 and TMEM242 help to assemble the rotor ring of human ATP synthase and interact with assembly factors for complex I - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8020751/#:~:text=organellar%20membrane%20of%20human%20ATP,and%2C%20as%20we%20demonstrate%2C%20TMEM242')
28. AnnotationURLCitation(end_index=10724, start_index=10565, title='TMEM70 and TMEM242 help to assemble the rotor ring of human ATP synthase and interact with assembly factors for complex I - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8020751/#:~:text=complexes%20I%2C%20III%2C%20and%20IV,the%20regulation%20of%20their%20levels')
29. AnnotationURLCitation(end_index=11370, start_index=11187, title='TMEM70 forms oligomeric scaffolds within mitochondrial cristae promoting in situ assembly of mammalian ATP synthase proton channel - ScienceDirect', type='url_citation', url='https://www.sciencedirect.com/science/article/pii/S0167488920303001#:~:text=status%20of%20other%20ATP%20synthase,mammalian%20ATP%20synthase%20is%20assembled')
30. AnnotationURLCitation(end_index=11703, start_index=11512, title='TMEM70 forms oligomeric scaffolds within mitochondrial cristae promoting in situ assembly of mammalian ATP synthase proton channel - ScienceDirect', type='url_citation', url='https://www.sciencedirect.com/science/article/pii/S0167488920303001#:~:text=experiments%20reveal%20that%20TMEM70%20forms,mammalian%20ATP%20synthase%20is%20assembled')
31. AnnotationURLCitation(end_index=12145, start_index=11962, title='TMEM70 forms oligomeric scaffolds within mitochondrial cristae promoting in situ assembly of mammalian ATP synthase proton channel - ScienceDirect', type='url_citation', url='https://www.sciencedirect.com/science/article/pii/S0167488920303001#:~:text=status%20of%20other%20ATP%20synthase,mammalian%20ATP%20synthase%20is%20assembled')
32. AnnotationURLCitation(end_index=12670, start_index=12484, title='TMEM70 forms oligomeric scaffolds within mitochondrial cristae promoting in situ assembly of mammalian ATP synthase proton channel - ScienceDirect', type='url_citation', url='https://www.sciencedirect.com/science/article/pii/S0167488920303001#:~:text=complexes%20with%20increasing%20Su,assembled%20within%20inner%20cristae%20membranes')
33. AnnotationURLCitation(end_index=13129, start_index=12933, title='TMEM70 forms oligomeric scaffolds within mitochondrial cristae promoting in situ assembly of mammalian ATP synthase proton channel - ScienceDirect', type='url_citation', url='https://www.sciencedirect.com/science/article/pii/S0167488920303001#:~:text=experiments%20reveal%20that%20TMEM70%20forms,assembled%20within%20inner%20cristae%20membranes')
34. AnnotationURLCitation(end_index=13571, start_index=13423, title='Genetic Complementation of ATP Synthase Deficiency Due to Dysfunction of TMEM70 Assembly Factor in Rat - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8869460/#:~:text=insufficient%20energy%20provision,of%20the%20controls%20in%20the')
35. AnnotationURLCitation(end_index=13733, start_index=13572, title='Genetic Complementation of ATP Synthase Deficiency Due to Dysfunction of TMEM70 Assembly Factor in Rat - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8869460/#:~:text=viable%20animals%20that%20showed%20the,rats%20resulted%20in%20the%20efficient')
36. AnnotationURLCitation(end_index=14048, start_index=13900, title='Genetic Complementation of ATP Synthase Deficiency Due to Dysfunction of TMEM70 Assembly Factor in Rat - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8869460/#:~:text=insufficient%20energy%20provision,of%20the%20controls%20in%20the')
37. AnnotationURLCitation(end_index=14499, start_index=14324, title='Genetic Complementation of ATP Synthase Deficiency Due to Dysfunction of TMEM70 Assembly Factor in Rat - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8869460/#:~:text=hypertensive%20rats%20with%20the%20targeted,for%20mitochondrial%20energetic%20function%20in')
38. AnnotationURLCitation(end_index=14645, start_index=14500, title='Genetic Complementation of ATP Synthase Deficiency Due to Dysfunction of TMEM70 Assembly Factor in Rat - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8869460/#:~:text=the%20liver,an%20otherwise%20fatal%20mitochondrial%20disorder')
39. AnnotationURLCitation(end_index=15020, start_index=14859, title='Genetic Complementation of ATP Synthase Deficiency Due to Dysfunction of TMEM70 Assembly Factor in Rat - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8869460/#:~:text=viable%20animals%20that%20showed%20the,rats%20resulted%20in%20the%20efficient')
40. AnnotationURLCitation(end_index=15379, start_index=15218, title='Genetic Complementation of ATP Synthase Deficiency Due to Dysfunction of TMEM70 Assembly Factor in Rat - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8869460/#:~:text=viable%20animals%20that%20showed%20the,rats%20resulted%20in%20the%20efficient')
41. AnnotationURLCitation(end_index=15734, start_index=15573, title='Genetic Complementation of ATP Synthase Deficiency Due to Dysfunction of TMEM70 Assembly Factor in Rat - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8869460/#:~:text=viable%20animals%20that%20showed%20the,rats%20resulted%20in%20the%20efficient')
42. AnnotationURLCitation(end_index=16037, start_index=15867, title='Genetic Complementation of ATP Synthase Deficiency Due to Dysfunction of TMEM70 Assembly Factor in Rat - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8869460/#:~:text=liver%20and%20heart%2C%20which%20was,an%20otherwise%20fatal%20mitochondrial%20disorder')
43. AnnotationURLCitation(end_index=17663, start_index=17480, title='ATP Synthase Deficiency due to TMEM70 Mutation Leads to Ultrastructural Mitochondrial Degeneration and Is Amenable to Treatment - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4621340/#:~:text=cardiomyopathy%2C%20facial%20dysmorphism%2C%20and%20psychomotor,data%20are%20available%20for%20most')
44. AnnotationURLCitation(end_index=17818, start_index=17664, title='ATP Synthase Deficiency due to TMEM70 Mutation Leads to Ultrastructural Mitochondrial Degeneration and Is Amenable to Treatment - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4621340/#:~:text=mitochondrial%20membrane%20,F1%CE%B1%20as%20assessed%20by%20immunogold')
45. AnnotationURLCitation(end_index=18474, start_index=18304, title='Genetic Complementation of ATP Synthase Deficiency Due to Dysfunction of TMEM70 Assembly Factor in Rat - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8869460/#:~:text=Mutations%20of%20the%20TMEM70%20gene,Tmem70%5E%7Bko%7D%5E%7B%2Fko%7D%20knockout%20rats')
46. AnnotationURLCitation(end_index=18932, start_index=18762, title='Genetic Complementation of ATP Synthase Deficiency Due to Dysfunction of TMEM70 Assembly Factor in Rat - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8869460/#:~:text=Mutations%20of%20the%20TMEM70%20gene,Tmem70%5E%7Bko%7D%5E%7B%2Fko%7D%20knockout%20rats')
47. AnnotationURLCitation(end_index=19093, start_index=18933, title='ATP Synthase Deficiency due to TMEM70 Mutation Leads to Ultrastructural Mitochondrial Degeneration and Is Amenable to Treatment - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4621340/#:~:text=Defects%20of%20nuclear%20genes%20resulting,function%20has%20not%20yet%20been')
48. AnnotationURLCitation(end_index=19735, start_index=19583, title='ATP Synthase Deficiency due to TMEM70 Mutation Leads to Ultrastructural Mitochondrial Degeneration and Is Amenable to Treatment - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4621340/#:~:text=mitochondrial%20membrane%20,tissue%20has%20rarely%20been%20performed')
49. AnnotationURLCitation(end_index=19899, start_index=19736, title='TMEM70 deficiency: long-term outcome of 48 patients - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/25326274/#:~:text=Results%3A%20All%2027%20Roma%20and,failure%2C%20accompanied%20by%20lactic%20acidosis')
50. AnnotationURLCitation(end_index=20186, start_index=20023, title='TMEM70 deficiency: long-term outcome of 48 patients - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/25326274/#:~:text=Results%3A%20All%2027%20Roma%20and,failure%2C%20accompanied%20by%20lactic%20acidosis')
51. AnnotationURLCitation(end_index=21222, start_index=21054, title='ATP Synthase Deficiency due to TMEM70 Mutation Leads to Ultrastructural Mitochondrial Degeneration and Is Amenable to Treatment - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4621340/#:~:text=emergency%20treatment%20aimed%20to%20convert,amino%20acids%20and%20possibly%20lipids')
52. AnnotationURLCitation(end_index=21392, start_index=21223, title='ATP Synthase Deficiency due to TMEM70 Mutation Leads to Ultrastructural Mitochondrial Degeneration and Is Amenable to Treatment - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4621340/#:~:text=crises%20and%20heart%20failure%20due,with%20offering%20alternative%20substrates%20for')
53. AnnotationURLCitation(end_index=21932, start_index=21764, title='ATP Synthase Deficiency due to TMEM70 Mutation Leads to Ultrastructural Mitochondrial Degeneration and Is Amenable to Treatment - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4621340/#:~:text=emergency%20treatment%20aimed%20to%20convert,amino%20acids%20and%20possibly%20lipids')
54. AnnotationURLCitation(end_index=22221, start_index=22053, title='ATP Synthase Deficiency due to TMEM70 Mutation Leads to Ultrastructural Mitochondrial Degeneration and Is Amenable to Treatment - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4621340/#:~:text=emergency%20treatment%20aimed%20to%20convert,amino%20acids%20and%20possibly%20lipids')
55. AnnotationURLCitation(end_index=22391, start_index=22222, title='ATP Synthase Deficiency due to TMEM70 Mutation Leads to Ultrastructural Mitochondrial Degeneration and Is Amenable to Treatment - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4621340/#:~:text=crises%20and%20heart%20failure%20due,with%20offering%20alternative%20substrates%20for')
56. AnnotationURLCitation(end_index=22844, start_index=22687, title='ATP Synthase Deficiency due to TMEM70 Mutation Leads to Ultrastructural Mitochondrial Degeneration and Is Amenable to Treatment - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4621340/#:~:text=months%2C%20child%20I%20was%20supposed,treatment%20most%20of%20the%20time')
57. AnnotationURLCitation(end_index=23123, start_index=22966, title='ATP Synthase Deficiency due to TMEM70 Mutation Leads to Ultrastructural Mitochondrial Degeneration and Is Amenable to Treatment - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4621340/#:~:text=months%2C%20child%20I%20was%20supposed,treatment%20most%20of%20the%20time')
58. AnnotationURLCitation(end_index=23537, start_index=23366, title='ATP Synthase Deficiency due to TMEM70 Mutation Leads to Ultrastructural Mitochondrial Degeneration and Is Amenable to Treatment - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4621340/#:~:text=of%20anaplerotic%20amino%20acids%2C%20lipids%2C,are%20still%20amenable%20to%20treatment')
59. AnnotationURLCitation(end_index=23666, start_index=23538, title='TMEM70 deficiency: long-term outcome of 48 patients - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/25326274/#:~:text=dysmorphism%20%2866,the%20age%20of%20five%20years')
60. AnnotationURLCitation(end_index=24149, start_index=23983, title='ATP Synthase Deficiency due to TMEM70 Mutation Leads to Ultrastructural Mitochondrial Degeneration and Is Amenable to Treatment - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4621340/#:~:text=pathology%20and%20treatment%20of%20ATP,methylglutaconic%20aciduria%20as%20clinical')
61. AnnotationURLCitation(end_index=24327, start_index=24150, title='TMEM70 deficiency: long-term outcome of 48 patients - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/25326274/#:~:text=lethargy%2C%20respiratory%20and%20heart%20failure%2C,emulsion%2C%20and%20ammonia%20scavengers%20or')
62. AnnotationURLCitation(end_index=24738, start_index=24591, title='TMEM70 deficiency: long-term outcome of 48 patients - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/25326274/#:~:text=or%20more%20acute%20metabolic%20crises,the%20age%20of%20five%20years')
63. AnnotationURLCitation(end_index=25313, start_index=25136, title='TMEM70 deficiency: long-term outcome of 48 patients - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/25326274/#:~:text=lethargy%2C%20respiratory%20and%20heart%20failure%2C,emulsion%2C%20and%20ammonia%20scavengers%20or')
64. AnnotationURLCitation(end_index=25479, start_index=25314, title='ATP Synthase Deficiency due to TMEM70 Mutation Leads to Ultrastructural Mitochondrial Degeneration and Is Amenable to Treatment - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4621340/#:~:text=crises%20as%20a%20promising%20treatment,of%20parents%20with%20affected%20children')
65. AnnotationURLCitation(end_index=25837, start_index=25678, title='ATP Synthase Deficiency due to TMEM70 Mutation Leads to Ultrastructural Mitochondrial Degeneration and Is Amenable to Treatment - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4621340/#:~:text=match%20at%20L47%20of%20anaplerotic,are%20still%20amenable%20to%20treatment')
66. AnnotationURLCitation(end_index=26448, start_index=26296, title='ATP Synthase Deficiency due to TMEM70 Mutation Leads to Ultrastructural Mitochondrial Degeneration and Is Amenable to Treatment - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4621340/#:~:text=mitochondrial%20membrane%20,tissue%20has%20rarely%20been%20performed')
67. AnnotationURLCitation(end_index=26941, start_index=26771, title='Genetic Complementation of ATP Synthase Deficiency Due to Dysfunction of TMEM70 Assembly Factor in Rat - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8869460/#:~:text=liver%20and%20heart%2C%20which%20was,an%20otherwise%20fatal%20mitochondrial%20disorder')
68. AnnotationURLCitation(end_index=28038, start_index=27870, title='TMEM70 and TMEM242 help to assemble the rotor ring of human ATP synthase and interact with assembly factors for complex I - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8020751/#:~:text=organellar%20membrane%20of%20human%20ATP,and%2C%20as%20we%20demonstrate%2C%20TMEM242')
69. AnnotationURLCitation(end_index=28400, start_index=28232, title='TMEM70 and TMEM242 help to assemble the rotor ring of human ATP synthase and interact with assembly factors for complex I - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8020751/#:~:text=organellar%20membrane%20of%20human%20ATP,and%2C%20as%20we%20demonstrate%2C%20TMEM242')
70. AnnotationURLCitation(end_index=29005, start_index=28819, title='TMEM70 forms oligomeric scaffolds within mitochondrial cristae promoting in situ assembly of mammalian ATP synthase proton channel - ScienceDirect', type='url_citation', url='https://www.sciencedirect.com/science/article/pii/S0167488920303001#:~:text=complexes%20with%20increasing%20Su,assembled%20within%20inner%20cristae%20membranes')
71. AnnotationURLCitation(end_index=29568, start_index=29440, title='TMEM70 facilitates biogenesis of mammalian ATP synthase by promoting subunit c incorporation into the rotor structure of the enzyme - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/31652072/#:~:text=of%20F_,spontaneous%20assembly%20of%20subunit%20c')
72. AnnotationURLCitation(end_index=30078, start_index=29933, title='TMEM70 facilitates biogenesis of mammalian ATP synthase by promoting subunit c incorporation into the rotor structure of the enzyme - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/31652072/#:~:text=TMEM70%20remains%20unknown,deficient%20cells.%20Altogether%2C%20we')
73. AnnotationURLCitation(end_index=30207, start_index=30079, title='TMEM70 facilitates biogenesis of mammalian ATP synthase by promoting subunit c incorporation into the rotor structure of the enzyme - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/31652072/#:~:text=of%20F_,spontaneous%20assembly%20of%20subunit%20c')
74. AnnotationURLCitation(end_index=30612, start_index=30441, title='ATP Synthase Deficiency due to TMEM70 Mutation Leads to Ultrastructural Mitochondrial Degeneration and Is Amenable to Treatment - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4621340/#:~:text=of%20anaplerotic%20amino%20acids%2C%20lipids%2C,are%20still%20amenable%20to%20treatment')
75. AnnotationURLCitation(end_index=30770, start_index=30613, title='ATP Synthase Deficiency due to TMEM70 Mutation Leads to Ultrastructural Mitochondrial Degeneration and Is Amenable to Treatment - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4621340/#:~:text=match%20at%20L510%20crises%20as,of%20parents%20with%20affected%20children')
76. AnnotationURLCitation(end_index=31121, start_index=30952, title='ATP Synthase Deficiency due to TMEM70 Mutation Leads to Ultrastructural Mitochondrial Degeneration and Is Amenable to Treatment - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4621340/#:~:text=match%20at%20L425%20treatment%20with,consisting%20basically%20of%20moderate%20glucose')
77. AnnotationURLCitation(end_index=31458, start_index=31311, title='TMEM70 deficiency: long-term outcome of 48 patients - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/25326274/#:~:text=or%20more%20acute%20metabolic%20crises,the%20age%20of%20five%20years')
78. AnnotationURLCitation(end_index=31809, start_index=31644, title='ATP Synthase Deficiency due to TMEM70 Mutation Leads to Ultrastructural Mitochondrial Degeneration and Is Amenable to Treatment - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4621340/#:~:text=crises%20as%20a%20promising%20treatment,of%20parents%20with%20affected%20children')
79. AnnotationURLCitation(end_index=32347, start_index=32176, title='ATP Synthase Deficiency due to TMEM70 Mutation Leads to Ultrastructural Mitochondrial Degeneration and Is Amenable to Treatment - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4621340/#:~:text=of%20anaplerotic%20amino%20acids%2C%20lipids%2C,are%20still%20amenable%20to%20treatment')
80. AnnotationURLCitation(end_index=33040, start_index=32934, title='TMEM70 facilitates biogenesis of mammalian ATP synthase by promoting subunit c incorporation into the rotor structure of the enzyme - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/31652072/#:~:text=match%20at%20L46%201,Sanger')
81. AnnotationURLCitation(end_index=33294, start_index=33153, title='Genetic Complementation of ATP Synthase Deficiency Due to Dysfunction of TMEM70 Assembly Factor in Rat - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8869460/#:~:text=which%20interacts%20with%20ATP11%20and,CI%29%20biogenesis')
82. AnnotationURLCitation(end_index=34098, start_index=33944, title='ATP Synthase Deficiency due to TMEM70 Mutation Leads to Ultrastructural Mitochondrial Degeneration and Is Amenable to Treatment - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4621340/#:~:text=mitochondrial%20membrane%20,F1%CE%B1%20as%20assessed%20by%20immunogold')
83. AnnotationURLCitation(end_index=34386, start_index=34216, title='Genetic Complementation of ATP Synthase Deficiency Due to Dysfunction of TMEM70 Assembly Factor in Rat - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8869460/#:~:text=Mutations%20of%20the%20TMEM70%20gene,Tmem70%5E%7Bko%7D%5E%7B%2Fko%7D%20knockout%20rats')
84. AnnotationURLCitation(end_index=34882, start_index=34719, title='TMEM70 deficiency: long-term outcome of 48 patients - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/25326274/#:~:text=Results%3A%20All%2027%20Roma%20and,failure%2C%20accompanied%20by%20lactic%20acidosis')
85. AnnotationURLCitation(end_index=35151, start_index=34988, title='TMEM70 deficiency: long-term outcome of 48 patients - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/25326274/#:~:text=Results%3A%20All%2027%20Roma%20and,failure%2C%20accompanied%20by%20lactic%20acidosis')
86. AnnotationURLCitation(end_index=35503, start_index=35349, title='ATP Synthase Deficiency due to TMEM70 Mutation Leads to Ultrastructural Mitochondrial Degeneration and Is Amenable to Treatment - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4621340/#:~:text=mitochondrial%20membrane%20,F1%CE%B1%20as%20assessed%20by%20immunogold')
87. AnnotationURLCitation(end_index=35839, start_index=35701, title='TMEM70 deficiency: long-term outcome of 48 patients - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/25326274/#:~:text=Arab%20Muslims%20and%20two%20Turkish,persistent%20pulmonary')
88. AnnotationURLCitation(end_index=36101, start_index=35936, title='TMEM70 deficiency: long-term outcome of 48 patients - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/25326274/#:~:text=Arab%20Muslims%20and%20two%20Turkish,failure%2C%20accompanied%20by%20lactic%20acidosis')
89. AnnotationURLCitation(end_index=36437, start_index=36290, title='TMEM70 deficiency: long-term outcome of 48 patients - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/25326274/#:~:text=or%20more%20acute%20metabolic%20crises,the%20age%20of%20five%20years')
90. AnnotationURLCitation(end_index=36713, start_index=36566, title='TMEM70 deficiency: long-term outcome of 48 patients - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/25326274/#:~:text=or%20more%20acute%20metabolic%20crises,the%20age%20of%20five%20years')
91. AnnotationURLCitation(end_index=37149, start_index=37042, title='Common and Novel TMEM70 Mutations in a Cohort of Italian Patients with Mitochondrial Encephalocardiomyopathy - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4270871/#:~:text=,C%C3%ADzkov%C3%A1%20et')
92. AnnotationURLCitation(end_index=37640, start_index=37471, title='TMEM70 deficiency: long-term outcome of 48 patients - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/25326274/#:~:text=lethargy%2C%20respiratory%20and%20heart%20failure%2C,White%20syndrome%20%2813%25%29.%20One')
93. AnnotationURLCitation(end_index=37957, start_index=37788, title='TMEM70 deficiency: long-term outcome of 48 patients - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/25326274/#:~:text=lethargy%2C%20respiratory%20and%20heart%20failure%2C,White%20syndrome%20%2813%25%29.%20One')
94. AnnotationURLCitation(end_index=38271, start_index=38102, title='TMEM70 deficiency: long-term outcome of 48 patients - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/25326274/#:~:text=lethargy%2C%20respiratory%20and%20heart%20failure%2C,White%20syndrome%20%2813%25%29.%20One')
95. AnnotationURLCitation(end_index=38602, start_index=38433, title='TMEM70 deficiency: long-term outcome of 48 patients - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/25326274/#:~:text=lethargy%2C%20respiratory%20and%20heart%20failure%2C,White%20syndrome%20%2813%25%29.%20One')
96. AnnotationURLCitation(end_index=38899, start_index=38753, title='TMEM70 deficiency: long-term outcome of 48 patients - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/25326274/#:~:text=developmental%20delay%20%2898,White%20syndrome%20%2813%25%29.%20One')
97. AnnotationURLCitation(end_index=39270, start_index=39124, title='TMEM70 deficiency: long-term outcome of 48 patients - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/25326274/#:~:text=developmental%20delay%20%2898,White%20syndrome%20%2813%25%29.%20One')
98. AnnotationURLCitation(end_index=39612, start_index=39466, title='TMEM70 deficiency: long-term outcome of 48 patients - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/25326274/#:~:text=developmental%20delay%20%2898,White%20syndrome%20%2813%25%29.%20One')
99. AnnotationURLCitation(end_index=39866, start_index=39711, title='TMEM70 deficiency: long-term outcome of 48 patients - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/25326274/#:~:text=developmental%20delay%20%2898,in%2024%20surviving%20children%2C%20frequently')
100. AnnotationURLCitation(end_index=40438, start_index=40271, title='ATP Synthase Deficiency due to TMEM70 Mutation Leads to Ultrastructural Mitochondrial Degeneration and Is Amenable to Treatment - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4621340/#:~:text=transmembrane%20protein%2070%20,with%20different%20genetically%20confirmed%20TMEM70')
101. AnnotationURLCitation(end_index=40719, start_index=40570, title='TMEM70 deficiency: long-term outcome of 48 patients - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/25326274/#:~:text=onset%20was%20neonatal%20in%2041,White%20syndrome%20%2813%25%29.%20One')
102. AnnotationURLCitation(end_index=41236, start_index=41108, title='TMEM70 deficiency: long-term outcome of 48 patients - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/25326274/#:~:text=dysmorphism%20%2866,the%20age%20of%20five%20years')
103. AnnotationURLCitation(end_index=41607, start_index=41437, title='Genetic Complementation of ATP Synthase Deficiency Due to Dysfunction of TMEM70 Assembly Factor in Rat - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8869460/#:~:text=Mutations%20of%20the%20TMEM70%20gene,Tmem70%5E%7Bko%7D%5E%7B%2Fko%7D%20knockout%20rats')
104. AnnotationURLCitation(end_index=41862, start_index=41718, title='Common and Novel TMEM70 Mutations in a Cohort of Italian Patients with Mitochondrial Encephalocardiomyopathy - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4270871/#:~:text=reduction,activities%20by%20disrupting%20the%20mitochondrial')
105. AnnotationURLCitation(end_index=42138, start_index=42000, title='Common and Novel TMEM70 Mutations in a Cohort of Italian Patients with Mitochondrial Encephalocardiomyopathy - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC4270871/#:~:text=reduction,cV%20impairment%20could%20indirectly%20alter')
106. AnnotationURLCitation(end_index=42753, start_index=42635, title='Common and Novel TMEM70 Mutations in a Cohort of Italian Patients with Mitochondrial Encephalocardiomyopathy - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/24740313/#:~:text=,to%20embryonal%20lethality%20in%20mice')
107. AnnotationURLCitation(end_index=43151, start_index=42990, title='Genetic Complementation of ATP Synthase Deficiency Due to Dysfunction of TMEM70 Assembly Factor in Rat - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8869460/#:~:text=viable%20animals%20that%20showed%20the,rats%20resulted%20in%20the%20efficient')
108. AnnotationURLCitation(end_index=43484, start_index=43323, title='Genetic Complementation of ATP Synthase Deficiency Due to Dysfunction of TMEM70 Assembly Factor in Rat - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC8869460/#:~:text=viable%20animals%20that%20showed%20the,rats%20resulted%20in%20the%20efficient')